Study of Tiprogrel in the Treatment of High-risk Patients with Acute Ischemic Cerebrovascular Events (THRIVE).

A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 600 participants.

Also called NCT06601127

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 600 participants (planned count) (from the registry)
Sponsor
Tianjin Institute of Pharmaceutical Research Co., Ltd (from the registry)
Registry
  • NCT NCT06601127
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT06601127. Randomized; quadruple masking; primary purpose treatment. Start 2025-02-21 (actual); primary completion 2026-04-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Study of Tiprogrel in the Treatment of High-risk Patients with Acute Ischemic Cerebrovascular Events (THRIVE).
Intervention (Drug)
Tiprogrel
Intervention (Drug)
Tiprogrel
Intervention (Drug)
Clopidogrel
Lead sponsor
Tianjin Institute of Pharmaceutical Research Co., Ltd (class: other government)

Record details

Record id
cardio:ct-nct06601127
Content hash
6c35edfac0ecab014102a9c8954fc0b78c8ad9dbfbdbd19f5b2447c79e41f1b8